Upadacitinib
Abbvie
['upadacitinib', 'ibd']
this analysis includes 50% more patients than reported in the initial paper; both doses of upadacitinib performed significantly better than placebo in terms of the primary endpoint and key secondary endpoints #ibd #uegweek #uegweek22 #gitwitter 
The Lancet Gastroenterology & Hepatology publishes high-quality peer-reviewed research and reviews, comment, and news #gastroenterology #hepatology. IF=45.042